ULS vs. ARWR
ULS (UL Solutions Inc) and ARWR (Arrowhead Pharmaceuticals, Inc.) are both stocks. ULS operates in Specialty Business Services (Industrials), while ARWR operates in Biotechnology (Healthcare). Over the past year, ULS returned 40.78% vs 336.79% for ARWR. At a 0.16 correlation, their price movements are largely independent.
Performance
ULS vs. ARWR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ULS achieves a 24.71% return, which is significantly higher than ARWR's 9.28% return.
ULS
- 1D
- 0.27%
- 1M
- 8.96%
- YTD
- 24.71%
- 6M
- 23.89%
- 1Y
- 40.78%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ARWR
- 1D
- 2.44%
- 1M
- -5.03%
- YTD
- 9.28%
- 6M
- 11.49%
- 1Y
- 336.79%
- 3Y*
- 26.25%
- 5Y*
- -0.96%
- 10Y*
- 28.05%
ULS vs. ARWR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ULS UL Solutions Inc | 24.71% | 59.33% | 43.88% |
ARWR Arrowhead Pharmaceuticals, Inc. | 9.28% | 253.14% | -23.89% |
Correlation
The correlation between ULS and ARWR is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Apr 15, 2024 | 0.16 |
Fundamentals
ULS:
$20.00B
ARWR:
$10.33B
ULS:
$1.71
ARWR:
-$2.16
ULS:
6.42
ARWR:
16.27
ULS:
14.97
ARWR:
17.25
ULS:
$3.11B
ARWR:
$622.01M
ULS:
$1.54B
ARWR:
$529.27M
ULS:
$725.35M
ARWR:
-$168.38M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ULS vs. ARWR — Risk / Return Rank
ULS
ARWR
ULS vs. ARWR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for UL Solutions Inc (ULS) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ULS | ARWR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.23 | ||
| Sortino ratioReturn per unit of downside risk | -3.00 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.59 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | 1.68 | 13.77 | -12.09 |
| Martin ratioReturn relative to average drawdown | 4.29 | 37.74 | -33.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ULS | ARWR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 5.22 | -4.23 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.01 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.38 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 1.78 | -0.01 | +1.79 |
Drawdowns
ULS vs. ARWR - Drawdown Comparison
The maximum ULS drawdown since its inception was -24.34%, smaller than the maximum ARWR drawdown of -99.24%. Use the drawdown chart below to compare losses from any high point for ULS and ARWR.
Loading charts...
Drawdown Indicators
| ULS | ARWR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -24.34% | -99.24% | +74.90% |
Max Drawdown (1Y)Largest decline over 1 year | -24.34% | -24.64% | +0.30% |
Max Drawdown (3Y)Largest decline over 3 years | — | -74.70% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -88.94% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -88.96% | — |
Current DrawdownCurrent decline from peak | -6.40% | -55.35% | +48.95% |
Average DrawdownAverage peak-to-trough decline | -5.58% | -81.24% | +75.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.53% | 8.97% | +0.56% |
Volatility
ULS vs. ARWR - Volatility Comparison
UL Solutions Inc (ULS) and Arrowhead Pharmaceuticals, Inc. (ARWR) have volatilities of 17.28% and 17.17%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ULS | ARWR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.28% | 17.17% | +0.11% |
Volatility (6M)Calculated over the trailing 6-month period | 32.27% | 39.41% | -7.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 41.32% | 65.03% | -23.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 35.86% | 65.03% | -29.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.86% | 74.14% | -38.28% |
Dividends
ULS vs. ARWR - Dividend Comparison
ULS's dividend yield for the trailing twelve months is around 0.56%, while ARWR has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
ARWR Arrowhead Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% |
ULS UL Solutions Inc | 0.56% | 0.66% | 0.75% |
Financials
ULS vs. ARWR - Financials Comparison
This section allows you to compare key financial metrics between UL Solutions Inc and Arrowhead Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ULS and ARWR have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ULS has higher volatility (17.28%) compared to ARWR (17.17%). In terms of maximum drawdown, ULS dropped -24.34% vs ARWR's -99.24%.
ARWR currently has the higher Sharpe Ratio (5.22 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ULS and ARWR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer